Erasca, Inc.

NASDAQ:ERAS

Biotechnology

Healthcare
$13.76 -0.14%

-$0.02 today

Market cap
$4.83B
Beta
0.73
P/E (TTM)
-15.3
EPS (TTM)
-$0.91
52W Low $1.21High $24.28

Volume 8.94M

Average 6.79M

Returns on capital

Erasca, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-38.3%

avg -29.7%

ROIC

-35.3%

avg -44.6%

ROA

-31.4%

avg -38.6%

Analysis

ROA is currently the strongest return metric at -31.4% versus its period average of -38.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Jonathan E. Lim

Co-Founder, Chairman & Chief Executive OfficerUSD 1.16M542.00M0.64%

David Chacko

Chief Financial Officer & Chief Business OfficerUSD 775.22K43——

Shannon Morris

Chief Medical OfficerUSD 772.7K560<0.01%

Ebun S. Garner

Chief Legal Officer & Corporate SecretaryUSD 607.44K54——

Michael D. Varney

Chairman of Research & Development, Scientific Advisory Board Member and DirectorUSD 93.18K68——

Lisa Tesvich-Bonora

Chief People Officer————

Nicholas Chetwyn

Chief Operating Officer————

Brian L. Baker

Senior Vice President of Finance—59——

Chandra D. Lovejoy

Chief Regulatory Affairs Officer—55——

Robert Shoemaker

Chief Scientific Officer—45——

Alison Tjosvold Milhous

Senior Vice President of Accounting—47——

Nik Chetwyn

Chief Operating Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 4, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

3

$2.28M

Net Transaction Value

−$2.28M

Net selling

Most Active

Garner Ebun

2 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Apr 1, 26

Garner Ebun

Direct

Sell$1.3M
Mar 4, 26

Morris Shannon

Direct

Sell$300.8K
Jan 7, 26

Garner Ebun

Direct

Sell$670.8K

Summary

Insiders reported 0 buys worth $0.00 and 3 sells worth $2.28M over the last 12 months. That adds up to net selling of $2.28M. Garner Ebun was the most active insider with 2 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/AN/A
N/A3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Erasca, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ERAS's management, answered from reported figures.

Who manages ERAS?

Erasca, Inc. (ERAS) lists 12 active executives. The top listed executive is Lisa Tesvich-Bonora, Chief People Officer.

Are ERAS insiders buying or selling?

Recent insider activity shows net buying of $142.28M.